Novel optically active clausenamides, process of the preparation thereof, pharmaceutical composition containing the same and their medical use
AssigneeInstitute of Materia Medica, Chinese Academy of Medical Sciences
InventorsJuntian Zhang, Liang Huang, Kemei Wu, Shiming Chen
Life of this patent
Estimating the term…
Abstract
The present invention relates to some new optically active clausenamide derivatives, process of the preparation thereof, a pharmaceutical composition containing the same and their medical use, particularly their use in the respects of hypoxia protective, nootropic and neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.
Claims9
Levoclausenamide of formula I
- 15
A optically active chiral compound of formula II,
- 16
- wherein said derivative is selected from one of the following compounds:
- 3S4R5R6R (−) epiclausenamide,
- 3R4S5S6S (+)epiclausenamide,
- 3S4R5S6R (−)neoclausenamide,
- 3R4S5R6S (+)neoclausenamide,
- 3S4R5S6S(−)epineoclausenamide,
- 3R4S5R6R(+)epineoclausen amide,
- 3S4S5S6R (+)cisclausenamide,
- 3R4R5R6S (−)cisclausenamide,
- 3S4S5S6S (+)cisepiclausenamide,
- 3R4R5R6R (−)cisepiclausenamide,
- 3S4S5R6S (−)cisneoclausenamide,
- 3R4R5S6R (+)cisneoclausenamide,
- 3S4S5R6R(−)cisepineoclausenamide, and
- 3R4R5S6S(+)cisepineoclausen-amide.
A pharmaceutical composition comprising an optically active compound of formula I and/or II and pharmaceutically carrier or excipient.
A pharmaceutical composition for the prevention and/or treatment of comprising an optically active compound of formula I and/or II and pharmaceutically carrier or excipient.
A use of an optically active compound of formula I and/or II for the manufacture of medicament for the perention and/or treatment of neurodegenerative disease such as cerebral ischemia, Alzheimer disease and vascular dementia.
A method for the prvention and/or treatment of neurodegenerative disease comprising administrating to a patient suffered with neurodegenerative disease or high risk of neurodegenrative disease an effective prevention and/or treatment amount of an optically active compound of formula I and/or II.
A use of an optically active compound of formula I and/or II for the manufacture of medicament for the prevention and/or treatment of neurodeganerative diseases.
A process of the preparation of levoclausenamide, which characterized in that:
- 1. De novo synthesis by using intramoleuclar inductive asymmetrical Dargen reaction to prepare compound (2*);
- 17
- 2. Biocatalystic resolution of said compound (2*);
- or
- 3. Chemical resolution of the racemic clausenamidone of formula (5*)
- 18
A process for preparaing an optical active clausenamide derivatives selected from the following compounds:
- 3S4R5R6R (−) epiclausenamide,
- 3R4S5S6S (+)epiclausenamide,
- 3S4R5S6R (−)neoclausenamide,
- 3R4S5R6S (+)neoclausenamide,
- 3S4R5S6S(−)epineoclausenamide,
- 3R4S5R6R(+)epineoclausen amide,
- 3S4S5S6R (+)cisclausenamide,
- 3R4R5R6S (−)cisclausenamide,
- 3S4S5S6S (+)cisepiclausenamide,
- 3R4R5R6R (−)cisepiclausenamide,
- 3S4S5R6S (−)cisneoclausenamide,
- 3R4R5S6R (+)cisneoclausenamide,
- 3S4S5R6R(−)cisepineoclausenamide, and
- 3R4R5S6S(+)cisepineoclausen-amide,
- said process is shown in scheme 4
- 19
- Note:
- (i)base catalyzed cyclization, NaOCH3 or (CH3)4NOH
- (j)resolution, resolving agent (−)menthyoxyl acetyl chloride
- (k) derivation of C3—OH by dihydropyan or acetylchloride/pyridine
- (l)reduction of C6═O by reducing agent NaBH4 or 1-selectride
- (m) reduction of C6═O by reducing agent Al(i-C3H7O)3
- (n) oxidation of C3—OH by oxidizing agent, K2Cr2O7/H+, or KmnO4+CuSO4, MnO2 or DMSO/(COCl)2
- (o) reduction of 2,3 by NaBH4/H+, or NaBH4/AlCl3, or catalytic hydrogenation
- (p) invertion of C3—OH by DIAD or DEAD/TPP, H+(mitsunobu method) or by CsOAc/18-crown-8, or
- said process is shown in scheme 5 wherein starting compound from a know compound racemic 3-deoxyepiclausenamide:
- 20
Dependencies are inferred from the claim text.